What ADC Therapeutics SA does.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA received accelerated approval from the U.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma (“DLBCL”) through our LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination) as well as into indolent lymphomas, including marginal zone lymphoma (“MZL”) and follicular lymphoma (”FL”), through investigator-initiated trials (“IITs”) at leading institutions.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical development to manufacturing and commercialization.

Revenue and profit, by fiscal year.

More on ADCT.

• ADC Therapeutics SA summary
• ADC Therapeutics SA financial statements
• ADC Therapeutics SA key metrics
• ADC Therapeutics SA health scores and style box
• ADC Therapeutics SA earnings
• ADC Therapeutics SA dividends
• ADC Therapeutics SA valuation
• ADC Therapeutics SA ownership and insiders
• ADC Therapeutics SA peers

Figures from ADC Therapeutics SA's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.